Avalo Therapeutics (AVTX) Shares Outstanding (2014 - 2026)

Avalo Therapeutics has reported Shares Outstanding for 13 years, with the latest figure at $24.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 127.55% year-over-year to $24.6 million; the trailing twelve-month figure through Mar 2026 stood at $24.6 million (up 127.55% YoY), and the FY2025 full-year result was $18.5 million, up 76.78% from the prior year.
• Shares Outstanding for Q1 2026 stood at $24.6 million, up from $18.5 million in the prior quarter.
• The five-year high for Shares Outstanding was $24.6 million in Q1 2026, with the low at $39294.0 in Q4 2022.
• Historically, Shares Outstanding has averaged $7.9 million across 5 years, with a median of $9.4 million in 2022.
• The largest YoY upside for Shares Outstanding was 1940.38% in 2023 against a maximum downside of 99.41% in 2023.
• Avalo Therapeutics' Shares Outstanding stood at $39294.0 in 2022, then surged by 1940.38% to $801746.0 in 2023, then soared by 1206.14% to $10.5 million in 2024, then jumped by 76.78% to $18.5 million in 2025, then jumped by 33.09% to $24.6 million in 2026.
• The last three Shares Outstanding figures came in at $24.6 million (Q1 2026), $18.5 million (Q4 2025), and $17.8 million (Q3 2025), per Business Quant data.